Trends of clinical trials for drug development in rare diseases

Ryuichi Sakate, Akiko Fukagawa, Yuri Takagaki, Hanayuki Okura, Akifumi Matsuyama

Research output: Contribution to journalArticle

Abstract

Background: Drug development for rare diseases is challenging because it is difficult to obtain relevant data from very few patients. It must be informative to grasp current status of clinical trials for drug development in rare diseases. Objective: Clinical trials in rare diseases are to be outlined and compared among the US, EU and Japan. Method: ClinicalTrials.gov (NCT, National Clinical Trial), EU Clinical Trials Register (EUCTR) and the Japan Primary Registries Network (JPRN) were analyzed. Clinical trials involving information on rare diseases and drugs were extracted by text-mining, based on the diseases and drugs derived from Orphanet and DrugBank, respectively. Results: In total, 28,526 clinical trials were extracted, which studied 1,535 rare diseases and 1,539 drugs. NCT had the largest number of trials, involving 1,252 diseases and 1,332 drugs. EUCTR and JPRN also had registry-specific diseases (250 and 22, respectively) and drugs (172 and 29, respectively) that should not be missed. Among the 1,535 rare diseases, most diseases were studied in only a limited number of trials; 70% of diseases were studied in fewer than 10 trials, and 28% were studied in only one. Additionally, most studied rare diseases were cancer-related ones. Conclusion: This study has revealed the characteristics of the clinical trials in rare diseases among the US, EU and Japan. The number of trials for rare diseases was limited especially for non-cancerrelated ones. This information could contribute to drug development such as drug-repositioning in rare diseases.

Original languageEnglish
Pages (from-to)199-208
Number of pages10
JournalCurrent Clinical Pharmacology
Volume13
Issue number3
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Rare Diseases
Clinical Trials
Pharmaceutical Preparations
Japan
Registries
Drug Repositioning
Data Mining

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Sakate, Ryuichi ; Fukagawa, Akiko ; Takagaki, Yuri ; Okura, Hanayuki ; Matsuyama, Akifumi. / Trends of clinical trials for drug development in rare diseases. In: Current Clinical Pharmacology. 2018 ; Vol. 13, No. 3. pp. 199-208.
@article{bd9a12f2ef1d4442a8d0e6f8fea9b924,
title = "Trends of clinical trials for drug development in rare diseases",
abstract = "Background: Drug development for rare diseases is challenging because it is difficult to obtain relevant data from very few patients. It must be informative to grasp current status of clinical trials for drug development in rare diseases. Objective: Clinical trials in rare diseases are to be outlined and compared among the US, EU and Japan. Method: ClinicalTrials.gov (NCT, National Clinical Trial), EU Clinical Trials Register (EUCTR) and the Japan Primary Registries Network (JPRN) were analyzed. Clinical trials involving information on rare diseases and drugs were extracted by text-mining, based on the diseases and drugs derived from Orphanet and DrugBank, respectively. Results: In total, 28,526 clinical trials were extracted, which studied 1,535 rare diseases and 1,539 drugs. NCT had the largest number of trials, involving 1,252 diseases and 1,332 drugs. EUCTR and JPRN also had registry-specific diseases (250 and 22, respectively) and drugs (172 and 29, respectively) that should not be missed. Among the 1,535 rare diseases, most diseases were studied in only a limited number of trials; 70{\%} of diseases were studied in fewer than 10 trials, and 28{\%} were studied in only one. Additionally, most studied rare diseases were cancer-related ones. Conclusion: This study has revealed the characteristics of the clinical trials in rare diseases among the US, EU and Japan. The number of trials for rare diseases was limited especially for non-cancerrelated ones. This information could contribute to drug development such as drug-repositioning in rare diseases.",
author = "Ryuichi Sakate and Akiko Fukagawa and Yuri Takagaki and Hanayuki Okura and Akifumi Matsuyama",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1574884713666180604081349",
language = "English",
volume = "13",
pages = "199--208",
journal = "Current Clinical Pharmacology",
issn = "1574-8847",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

Trends of clinical trials for drug development in rare diseases. / Sakate, Ryuichi; Fukagawa, Akiko; Takagaki, Yuri; Okura, Hanayuki; Matsuyama, Akifumi.

In: Current Clinical Pharmacology, Vol. 13, No. 3, 01.01.2018, p. 199-208.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Trends of clinical trials for drug development in rare diseases

AU - Sakate, Ryuichi

AU - Fukagawa, Akiko

AU - Takagaki, Yuri

AU - Okura, Hanayuki

AU - Matsuyama, Akifumi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Drug development for rare diseases is challenging because it is difficult to obtain relevant data from very few patients. It must be informative to grasp current status of clinical trials for drug development in rare diseases. Objective: Clinical trials in rare diseases are to be outlined and compared among the US, EU and Japan. Method: ClinicalTrials.gov (NCT, National Clinical Trial), EU Clinical Trials Register (EUCTR) and the Japan Primary Registries Network (JPRN) were analyzed. Clinical trials involving information on rare diseases and drugs were extracted by text-mining, based on the diseases and drugs derived from Orphanet and DrugBank, respectively. Results: In total, 28,526 clinical trials were extracted, which studied 1,535 rare diseases and 1,539 drugs. NCT had the largest number of trials, involving 1,252 diseases and 1,332 drugs. EUCTR and JPRN also had registry-specific diseases (250 and 22, respectively) and drugs (172 and 29, respectively) that should not be missed. Among the 1,535 rare diseases, most diseases were studied in only a limited number of trials; 70% of diseases were studied in fewer than 10 trials, and 28% were studied in only one. Additionally, most studied rare diseases were cancer-related ones. Conclusion: This study has revealed the characteristics of the clinical trials in rare diseases among the US, EU and Japan. The number of trials for rare diseases was limited especially for non-cancerrelated ones. This information could contribute to drug development such as drug-repositioning in rare diseases.

AB - Background: Drug development for rare diseases is challenging because it is difficult to obtain relevant data from very few patients. It must be informative to grasp current status of clinical trials for drug development in rare diseases. Objective: Clinical trials in rare diseases are to be outlined and compared among the US, EU and Japan. Method: ClinicalTrials.gov (NCT, National Clinical Trial), EU Clinical Trials Register (EUCTR) and the Japan Primary Registries Network (JPRN) were analyzed. Clinical trials involving information on rare diseases and drugs were extracted by text-mining, based on the diseases and drugs derived from Orphanet and DrugBank, respectively. Results: In total, 28,526 clinical trials were extracted, which studied 1,535 rare diseases and 1,539 drugs. NCT had the largest number of trials, involving 1,252 diseases and 1,332 drugs. EUCTR and JPRN also had registry-specific diseases (250 and 22, respectively) and drugs (172 and 29, respectively) that should not be missed. Among the 1,535 rare diseases, most diseases were studied in only a limited number of trials; 70% of diseases were studied in fewer than 10 trials, and 28% were studied in only one. Additionally, most studied rare diseases were cancer-related ones. Conclusion: This study has revealed the characteristics of the clinical trials in rare diseases among the US, EU and Japan. The number of trials for rare diseases was limited especially for non-cancerrelated ones. This information could contribute to drug development such as drug-repositioning in rare diseases.

UR - http://www.scopus.com/inward/record.url?scp=85058880345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058880345&partnerID=8YFLogxK

U2 - 10.2174/1574884713666180604081349

DO - 10.2174/1574884713666180604081349

M3 - Article

C2 - 29866013

AN - SCOPUS:85058880345

VL - 13

SP - 199

EP - 208

JO - Current Clinical Pharmacology

JF - Current Clinical Pharmacology

SN - 1574-8847

IS - 3

ER -